BioSpace News Archive

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that David-Alexandre C. Gros, MD, Chief Executive Officer, will be participating in the virtual Noble Capital Markets’ Seventeenth Annual Investor / Equity Conference

BioLineRx Ltd. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 12,500,000 American Depositary Shares of the Company, at a price to the public of $2.40 per ADS, less underwriting discounts and commissions.

Fulcrum Therapeutics, Inc. announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 4,166,667 American Depositary Shares

DJO, LLC (DJO or the Company), a leading global provider of medical technologies to get and keep people moving, today announced the acquisition of Trilliant Surgical®, a national provider of foot and ankle orthopedic implants. The acquisition of Trilliant Surgical’s leading product technologies and clinical efficacy supports DJO’s focused expansion

Lucid Audio® announces the launch of Engage™️ to evolve hearing healthcare as we know it.

EGF Theramed Health Corp. (CSE:TMED)(OTC PINK:EVAHF) (the “Company”) is pleased to announce that it has completed the second and final tranche of its previously announced (December 10, 2020 and December 15, 2021) offering (the “Offering”), issuing 1,466,666 units (each a “Unit”) by way of non-brokered private placement at a price of $0.12 per Unit for gross proceeds of $175,999.92.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical development for treatment of patients with COVID-19 disease

Signify Health, Inc. a leading value-based healthcare platform enabled by advanced analytics, technology and nationwide healthcare networks, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its Class A common stock